Tcr2 Therapeutics - TCRR STOCK NEWS

TCR2 Therapeutics (TCRR) reported its Q3 2022 financial results, highlighting ongoing advancements in its T cell therapies for solid tumors. The Phase 1 trial of gavo-cel showed positive outcomes, with 28 of 30 patients experiencing lesion regression. The company ended Q3 with $176 million in cash, down from $265.6 million at the end of 2021, with a projected net cash use of $115-125 million for the year. Net loss increased to $30.6 million from $26.2 million in Q3 2021. TCR2 continues to focus on clinical trials for gavo-cel and TC-510, aiming for significant patient access to investigational therapies.

TCR2 Therapeutics Inc. (Nasdaq: TCRR) presented new preclinical data at the SITC Conference, highlighting the functional activity of gavo-cel TRuC-T cells in relation to soluble mesothelin (sMSLN). The study found that even at high, supraphysiological levels, sMSLN did not impair the ability of gavo-cel T cells to kill tumor cells or produce cytokines. This suggests that sMSLN levels in patients with malignant pleural/peritoneal mesothelioma may not limit gavo-cel's clinical efficacy. The results bolster confidence in the therapeutic potential of gavo-cel against solid tumors.

TCR² Therapeutics Inc. (TCRR) announced the approval of inducement stock options for 2,600 shares to one non-executive employee. The options have an exercise price of $1.57, the closing market price on the grant date, and a ten-year term. They will vest over four years, with 25% vesting after one year and the remainder in monthly installments. This incentive is intended to attract and retain talent in the clinical-stage company focused on T cell therapies for solid tumors.

TCR² Therapeutics has announced the approval of inducement stock options for 19,400 shares to a new non-executive employee. The options have an exercise price of $1.80, equal to the closing market price on the grant date, and have a ten-year term with a four-year vesting period. TCR² is focused on developing T cell therapies aimed at solid tumors using its proprietary TRuC^®-T cell platform. The company is committed to innovation in cancer treatment and compliance with Nasdaq regulations.

TCR2 Therapeutics announced positive results from the Phase 1 portion of its gavo-cel clinical trial targeting mesothelin-expressing tumors. Key findings include a disease control rate of 77%, with 93% of evaluable patients showing tumor regression. The median progression-free survival was 5.6 months, and overall survival reached 11.2 months for mesothelioma patients. With Phase 2 underway, TCR2 aims to enhance outcomes through combinations with checkpoint inhibitors. The company plans to host a conference call on September 28, 2022, to discuss these developments further.

TCR² Therapeutics Inc. (Nasdaq: TCRR) announced a conference call scheduled for September 28, 2022, at 8:00 AM E.T., where details of the Phase 1 portion of its gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors will be discussed. The call can be accessed via registration, and a replay will be available for 30 days on the company’s website. TCR² is focused on developing innovative T cell therapies targeting solid tumors using its proprietary TRuC platform.

TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy firm, will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on September 29 at 2:00PM E.T. This event allows investors to gain insights into the company's innovative T cell therapies targeting solid tumors. A live webcast will be available on the company's Investors page, and a replay will be accessible for 30 days post-event.

TCR² develops proprietary TRuC^®-T cells designed to target cancer cells effectively.

TCR2 Therapeutics (Nasdaq: TCRR), a clinical-stage cell therapy company, announced the approval of inducement stock options for 2 new non-executive employees. The options total 7,600 shares at an exercise price of $2.72, the closing price on the grant date. The stock options will vest over four years, starting with 25% after one year, followed by monthly vesting over the next three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of TCR2's strategy to attract talent and develop its novel T cell therapies for solid tumors.

TCR2 Therapeutics Inc. (Nasdaq: TCRR) announced the approval of inducement stock options for 46,600 shares to two new non-executive employees, as per Nasdaq Listing Rule 5635(c)(4). The options, granted at an exercise price of $3.18, will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly over the next three years, contingent on continued employment. This move is part of TCR2's strategy to enhance its talent pool as it develops T cell therapies for solid tumors, utilizing its proprietary TRuC platform.